Sun Pharmaceutical Industries (NSE: SUNPHARMA) reported its second-quarter 2022 earnings results today.
The company reported consolidated revenue of ₹98.4 billion with a growth of 12% year on year.
Sun Pharma had a total net profit of ₹18 billion or ₹8.5 per share compared to ₹14 billion ₹7.6 per share in the same quarter of the previous year.
The company’s total expenses in the quarter rose 9.7% on-year to ₹76 billion, which boosted the operating performance.